Kayıkçıoğlu Meral
Department of Cardiology, Ege University Faculty of Medicine, İzmir, Turkey.
Turk Kardiyol Dern Ars. 2017 Apr;45(Suppl 3):8-12. doi: 10.5543/tkda.2017.80930.
HMG-CoA reductase inhibitors (statins) represent the most effective class of LDL lowering drugs with an overall positive safety and tolerability profile. They have also consistent benefit in terms of reduced cardiovascular (CV) events in both primary and secondary prevention. Pitavastatin is a new member of the statin class. This review provides a current overview of pravastatin's role in CV risk reduction. In brief pitatastatin has pleitrophic effects as the other statins. It has been shown that it reduces plaque atheroma volume in acute coranary settings. Also the 'real life' evidence gained with pitavastatin in LIVES study, a longterm postmarketing surveillance study in more than 20,000 patients in Japan, denotes an effective CV risk reduction with this new statin.
HMG-CoA还原酶抑制剂（他汀类药物）是最有效的降低低密度脂蛋白（LDL）的药物类别，总体安全性和耐受性良好。它们在一级和二级预防中减少心血管（CV）事件方面也具有持续的益处。匹伐他汀是他汀类药物中的新成员。本综述提供了普伐他汀在降低CV风险中作用的当前概述。简而言之，匹伐他汀与其他他汀类药物一样具有多效性。已表明它在急性冠脉情况下可减少斑块粥样瘤体积。此外，在日本对20000多名患者进行的长期上市后监测研究LIVES中使用匹伐他汀获得的“实际生活”证据表明，这种新型他汀类药物可有效降低CV风险。
